AFFiRiS is a clinical-stage biopharmaceutical company that pursues the ultimate aim to improve the lives of patients suffering from chronic diseases by providing specific active immunotherapies (SAIT) based on its proprietary patented AFFITOME® technology. We strive to deliver much-needed therapies for patients with chronic diseases.
We aim to surpass currently available treatments.
RECENT PRESS RELEASES
22 December 2021
AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China
27 July 2021
AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases
27 May 2021
Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology
11 September 2020
AFFiRiS announces late-breaking presentation of clinical PD01 data in Parkinson’s disease patients at the MDS Virtual Congress
10 September 2020
AFFiRiS announces publication in Movement Disorders Journal of positive clinical results of a Phase 1 trial in early Multiple System Atrophy
18 June 2020
The Lancet Neurology publishes positive results of AFFiRiS’ Phase 1 trial with PD01A in Parkinson’s disease patients
Specific Active ImmunoTherapy (SAIT)
Adherence to current therapies can be poor due to complex dosing regimens, and the treatment of many chronic diseases is still inadequate. Using our unique AFFITOME technology, we are developing Specific Active ImmunoTherapy (SAIT), which stimulates the body to find and fight proteins central to the development and progression of chronic diseases. SAIT induces a long‑lasting target-specific immune response, which may be generated by far less frequent dosing regimens (e.g., once or twice a year)
SAIT is an exciting prospect.
We focus on identifying proteins that are involved in the development and progression of chronic human diseases, and establishing novel SAIT treatments against potentially pathogenic forms of these proteins using our unique AFFITOME technology. SAIT has successfully demonstrated proof of concept in both preclinical and clinical studies. Our most advanced product candidates are ready to enter Phase II clinical trials.
We are moving forward.